Medical doctors, in collaboration with molecular virologists, designed a bacteriophage cocktail to treat a lethal bacterial infection in a patient suffering from cystic fibrosis. The cocktail contained a genetically modified bacteriophage and two selected wildtype phages. It is the first therapeutic use of genetically modified phages to treat a human mycobacterial infection. How do you consider the safety aspects, or how do you address moral and ethical issues?

Back to Case material.